Non-Nucleoside Building Blocks for Copper-Assisted and Copper-Free Click Chemistry for the Efficient Synthesis of RNA Conjugates
作者:K. N. Jayaprakash、Chang Geng Peng、David Butler、Jos P. Varghese、Martin A. Maier、Kallanthottathil G. Rajeev、Muthiah Manoharan
DOI:10.1021/ol102205j
日期:2010.12.3
Novel non-nucleoside alkyne monomers compatible with oligonucleotide synthesis were designed, synthesized, and efficiently incorporated into RNA and RNA analogues during solid-phase synthesis. These modifications allowed site-specific conjugation of ligands to the RNA oligonucleotides through copper-assisted (CuAAC) and copper-free strain-promoted azide−alkyne cycloaddition (SPAAC) reactions. The SPAAC
MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S)
申请人:Manoharan Muthiah
公开号:US20130053334A1
公开(公告)日:2013-02-28
The invention features compounds of formula (V) or(XII). In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.
US9198972B2
申请人:——
公开号:US9198972B2
公开(公告)日:2015-12-01
US9566340B2
申请人:——
公开号:US9566340B2
公开(公告)日:2017-02-14
[EN] MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S)<br/>[FR] MONOMÈRES ET OLIGONUCLÉOTIDES COMPRENANT UN OU PLUSIEURS ADDUITS DE CYCLOADDITION
申请人:ALNYLAM PHARMACUTICALS INC
公开号:WO2011100131A9
公开(公告)日:2011-10-20
[EN] The invention features compounds of formula (V) or( XII). In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. [FR] L'invention concerne des composés de formule (V) ou (XII). Dans un mode de réalisation, l'invention concerne des composés et des procédés pour conjuguer un ligand à un oligonucléotide. L'invention concerne en outre des méthodes pour traiter divers troubles et maladies de type infections virales, infections bactériennes, infections parasites, cancers, allergies, maladies auto-immunes, immunodéficiences et l'immunosuppression.